Načítá se...

GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty

BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Endocrinol (Lausanne)
Hlavní autoři: Zhu, Shunye, Long, Lingli, Hu, Yue, Tuo, Ying, Li, Yubin, Yu, Zhenhua
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8221533/
https://ncbi.nlm.nih.gov/pubmed/34177807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.678797
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!